Quanterix Co. (NASDAQ:QTRX) Shares Acquired by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC increased its holdings in Quanterix Co. (NASDAQ:QTRX) by 93.6% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 20,191 shares of the company’s stock after buying an additional 9,764 shares during the period. Los Angeles Capital Management LLC owned about 0.05% of Quanterix worth $476,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. AJOVista LLC acquired a new position in shares of Quanterix in the 4th quarter valued at about $81,000. DekaBank Deutsche Girozentrale acquired a new position in shares of Quanterix in the 3rd quarter valued at about $125,000. Picton Mahoney Asset Management acquired a new position in shares of Quanterix in the 4th quarter valued at about $139,000. Quest Partners LLC acquired a new position in shares of Quanterix in the 4th quarter valued at about $240,000. Finally, Graham Capital Management L.P. acquired a new position in shares of Quanterix in the 3rd quarter valued at about $287,000. 86.48% of the stock is owned by institutional investors and hedge funds.

Quanterix Price Performance

Quanterix stock opened at $12.68 on Wednesday. The firm has a 50 day simple moving average of $15.99 and a 200-day simple moving average of $21.50. The stock has a market capitalization of $485.26 million, a PE ratio of -13.21 and a beta of 1.50. Quanterix Co. has a 12-month low of $12.52 and a 12-month high of $29.70.

Quanterix (NASDAQ:QTRX) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.07. The business had revenue of $32.07 million during the quarter, compared to analysts’ expectations of $31.72 million. Quanterix had a negative net margin of 28.82% and a negative return on equity of 10.39%. On average, analysts forecast that Quanterix Co. will post -0.86 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on QTRX shares. Scotiabank upped their target price on shares of Quanterix from $30.00 to $32.00 and gave the stock a “sector outperform” rating in a research report on Monday, March 4th. Canaccord Genuity Group decreased their target price on shares of Quanterix from $32.00 to $25.00 and set a “buy” rating for the company in a research report on Monday, April 29th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Quanterix currently has a consensus rating of “Buy” and an average target price of $30.60.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.